It is important in several diseases, including chronic obstructive pulmonary disease, cystic fibrosis, and asthma, and clinical trials have been planned to target IL-17A as a treatment for patients with inadequately controlled or steroid-resistant asthma [6]. This evidence concerns the gene IL17A and asthma.